Data work in 2026 asks for more than chart building. Professionals are expected to clean data, query databases, explain trends, and present findings clearly across business, finance, product, and ...

UC San Diego cognitive scientist Philip Guo created Python Tutor, a free tool that makes code “visible” step by step. The research behind it earned a Test of Time award, recog ...

If you had walked onto a trading floor thirty years ago, you would have heard noise before you saw anything. Phones ringing, ...

animation in Python, visualizing the infinite, non-repeating nature of pi through dynamic graphics and mathematical patterns. You’ll learn how to use Python to generate digits of π, create smooth ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

Generate is indicative of a more mature startup that may have a better chance of succeeding in today’s markets. Industry IPOs peaked in 2021, resulting in a flood of companies whose early science didn ...